239 related articles for article (PubMed ID: 31104302)
1. Analysis of inflammatory cytokine expression in the urinary tract of BALB/c mice infected with Proteus (P.) mirabilis and enteroaggregative Escherichia (E.) coli (EAEC) strains.
Melendez-Avalos A; Sainz-Espuñes T; Castrillón-Rivera LE; Mendoza-Pérez F; Palma-Ramos A; Castañeda-Sánchez JI; Drago-Serrano EM
Folia Microbiol (Praha); 2020 Feb; 65(1):133-142. PubMed ID: 31104302
[TBL] [Abstract][Full Text] [Related]
2. Urine Cytokine and Chemokine Levels Predict Urinary Tract Infection Severity Independent of Uropathogen, Urine Bacterial Burden, Host Genetics, and Host Age.
Armbruster CE; Smith SN; Mody L; Mobley HLT
Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29891542
[TBL] [Abstract][Full Text] [Related]
3. Use of green fluorescent protein to assess urease gene expression by uropathogenic Proteus mirabilis during experimental ascending urinary tract infection.
Zhao H; Thompson RB; Lockatell V; Johnson DE; Mobley HL
Infect Immun; 1998 Jan; 66(1):330-5. PubMed ID: 9423875
[TBL] [Abstract][Full Text] [Related]
4. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P
Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860
[TBL] [Abstract][Full Text] [Related]
5. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
6. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
[TBL] [Abstract][Full Text] [Related]
7. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL
Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
[TBL] [Abstract][Full Text] [Related]
8. New aspects of RpoE in uropathogenic Proteus mirabilis.
Liu MC; Kuo KT; Chien HF; Tsai YL; Liaw SJ
Infect Immun; 2015 Mar; 83(3):966-77. PubMed ID: 25547796
[TBL] [Abstract][Full Text] [Related]
9. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
10. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection.
Zhao H; Li X; Johnson DE; Mobley HLT
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():185-195. PubMed ID: 10206698
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL
Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
13. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.
Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P
FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of Proteus mirabilis urinary tract infection.
Coker C; Poore CA; Li X; Mobley HL
Microbes Infect; 2000 Oct; 2(12):1497-505. PubMed ID: 11099936
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome of Proteus mirabilis in the murine urinary tract: virulence and nitrogen assimilation gene expression.
Pearson MM; Yep A; Smith SN; Mobley HL
Infect Immun; 2011 Jul; 79(7):2619-31. PubMed ID: 21505083
[TBL] [Abstract][Full Text] [Related]
18. Evidence that patients with rheumatoid arthritis have asymptomatic 'non-significant' Proteus mirabilis bacteriuria more frequently than healthy controls.
Senior BW; Anderson GA; Morley KD; Kerr MA
J Infect; 1999 Mar; 38(2):99-106. PubMed ID: 10342649
[TBL] [Abstract][Full Text] [Related]
19. Proteus mirabilis fimbriae (PMF) are important for both bladder and kidney colonization in mice.
Zunino P; Sosa V; Allen AG; Preston A; Schlapp G; Maskell DJ
Microbiology (Reading); 2003 Nov; 149(Pt 11):3231-3237. PubMed ID: 14600235
[TBL] [Abstract][Full Text] [Related]
20. The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection.
Jacobsen SM; Lane MC; Harro JM; Shirtliff ME; Mobley HL
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):180-93. PubMed ID: 18194341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
